Last updated: October 30, 2023
Sponsor: Clinique Ovo
Overall Status: Active - Recruiting
Phase
N/A
Condition
Testotoxicosis
Reproductive Health
Testotoxikose
Treatment
Ferriman-Gallwey Score
Clinical Study ID
NCT05555680
CCER 21-22 - 31
Ages 18-39 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Women between ages of 18 - 39 inclusively
- ≥15 oocytes collected on the day of oocyte retrieval and/or anti-mullerian hormone (AMH) ≥ 4.0 ng/ml in the participant's medical chart in the last 24 months
Exclusion
Exclusion Criteria:
- Male factor necessitating testicular sperm aspiration (TESA), testicular spermextraction (TESE) or micro-TESE
- Fertility preservation
- Recurrent pregnancy losses (RPL) (defined as 2 or more failed clinical pregnancies asdocumented by ultrasonography or histopathologic examination,or 3 or more failedpregnancies before 14 weeks of gestation)
- Oocyte donation
- Medical diagnosis of non classic congenital adrenal hyperplasia diagnosed based on 17hydroxyprogesterone level
Study Design
Total Participants: 188
Treatment Group(s): 1
Primary Treatment: Ferriman-Gallwey Score
Phase:
Study Start date:
January 21, 2022
Estimated Completion Date:
December 30, 2025
Study Description
Connect with a study center
Clinique Ovo
Montreal, Quebec H4P 2S4
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.